Product Details
| Product Name:
ZYN57939 |
CAS No.:
1639357-93-9 |
| Purity:
99.81% |
Supply Ability:
10g |
| Release date:
2026/04/22 |
Product Introduction
Bioactivity
| Name | ZYN57939 |
| Description | ZYN57939 (MTR-106) is RNA polymerase I inhibitor for treating RNA polymerase I- mediated diseases. ZYN57939 showed inhibitory activity with IC50 of 0.855 μM against human HT- 29 cancer cell lines. |
| In vitro | MTR-106, stabilizes DNA G-quadruplexes in vitro.?MTR-106 displayed significant antiproliferative activity in homologous recombination repair (HR)-deficient and PARP inhibitor (PARPi)-resistant cancer cells.?Moreover, MTR-106 increased DNA damage and promoted cell cycle arrest and apoptosis to inhibit cell growth. |
| In vivo | ZYN57939 oral and i.v. administration significantly impaired tumor growth in BRCA-deficient xenograft mouse models.However, ZYN57939 showed modest activity against talazoparib-resistant xenograft models.In rats, the drug rapidly distributes to tissues within 5 min, and its average concentrations were 12-fold higher in the tissues than in the plasma.Overall, ZYN57939 as a novel G-quadruplex stabilizer with high tissue distribution, and it may serve as a potential anticancer agent. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | DMSO : 5.26 mg/mL (10.01 mM), Sonication is recommended.
H2O : Insoluble
|
| Keywords | ZYN-57939 | ZYN57939 | ZYN 57939 | RNASynthesis | RNA Synthesis | RNA polymerase I | MTR106 | MTR 106 | DNASynthesis | DNA Synthesis |
| Inhibitors Related | Stavudine | Aceglutamide | Urea | Tamoxifen | Cysteamine hydrochloride | Guanidine hydrochloride | Metronidazole | Formamide | Thymidine | Dimethyl phthalate | Alginic acid | Sildenafil citrate |
| Related Compound Libraries | DNA Damage & Repair Compound Library | Bioactive Compound Library | Inhibitor Library | Anti-Aging Compound Library | Bioactive Compounds Library Max | Cell Cycle Compound Library | Anti-Cancer Compound Library | Anti-Cancer Active Compound Library |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
Recommended supplier
| Product name |
Price |
|
Suppliers |
Update time |
|
|
|
|
Anhui Ruihan Technology Co., Ltd
|
2023-08-21 |
United States